# Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma

> **NCT02249702** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 168 (actual)

## Conditions studied

- Leiomyosarcoma

## Interventions

- **DRUG:** gemcitabine + docetaxel
- **DRUG:** trabectedin

## Key facts

- **NCT ID:** NCT02249702
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2017-04-30
- **Final completion:** 2017-04-30
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2017-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249702, "Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02249702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*